FDA approves Sareptas Srp901 for the whole population, page-40

Here’s thing
Analysts are calling $187 per Sarepta share
That’s almost a MC of 18 billion $$

At the moment Sarepta have a MC of $16 billion
earnings are $353 million but they are yet to make a profit..

Some say Sarepta could earn $1 billion next year ?
Now
All the drugs have not shown efficacy or produced the end points in their trails

The FDA has definitely set a PRECEDENT

ok
So one can ask?
What’s it got to do with PER ?

In my opinion as long as the Tox study is a given
I firmly believe Atl1102 will be a winner
In DMD and LGMD

Do the sums .. a MC of $5 billion is reachable $$


https://www.bloomberg.com/news/newsl















https://www.bloomberg.com/news/newsl